Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844684 | 0.91 | MAPT (0.46) | CYP3A4CYP2D6PORCNPDE10ACYP26A1 | |
| SCHEMBL2452081 | 0.88 | ROCK2 (0.38) | CYP3A4CYP2D6PORCNSYKROCK2 | |
| SCHEMBL2445594 | 0.84 | SYK (0.39) | CYP3A4CYP2D6PORCNPDGFRBPDE10A | |
| SCHEMBL2483361 | 0.83 | ROCK2 (0.40) | CYP3A4CYP2D6PORCNPDGFRBPDE10A | |
| SCHEMBL2485293 | 0.81 | HTR2C (0.37) | CYP3A4CYP2D6PORCNSYKCYP26A1 | |
| SCHEMBL2448106 | 0.79 | NR3C2 (0.38) | CYP3A4CYP2D6PORCNPDGFRBPDE10A | |
| SCHEMBL2481692 | 0.79 | ADORA3 (0.39) | SYK | |
| SCHEMBL2448058 | 0.79 | GPBAR1 (0.37) | CYP3A4CYP2D6PORCNPDGFRBSYK | |
| SCHEMBL2451543 | 0.78 | SYK (0.41) | CYP3A4CYP2D6PORCNPDGFRBSYK | |
| SCHEMBL2446932 | 0.78 | SYK (0.46) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2367826-A1 | MODULATORS OF AMYLOID BETA. | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | CYP3A4 4727/4885CYP2D6 4725/4885PORCN 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.